Clinical Trial Update: A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors [Phase 1, Phase 2]

View source ↗

Summary

This phase 1/2 clinical trial update reports results for selpercatinib in pediatric participants with advanced solid tumors and primary CNS tumors, including me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infantile Fibrosarcoma
• Infantile Myofibromatosis
• Medullary Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Soft Tissue Sarcoma

Drugs mentioned

• Selpercatinib (selpercatinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Medullary Thyroid Cancer, Infantile Myofibromatosis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-06